Key Details
The amendment expands the CLAA framework to bring advanced cell and gene therapies under joint Central-State licensing, reflecting the growing regulatory complexity of emerging biomedical technologies.
Regulatory Aspect | Before Amendment | After Amendment |
|---|---|---|
Products covered under CLAA | Vaccines, recombinant DNA (r-DNA) drugs and other specified biological products | Cell or stem cell-derived products, gene therapeutic products and xenografts added to existing CLAA coverage |
Licensing mechanism | Joint Central-State licensing for specified biological products | Joint Central-State licensing extended to advanced therapies requiring specialised scientific oversight |
Regulatory objective | Uniform oversight for selected high-risk biological products | Uniform national licensing standards expanded to emerging regenerative and gene-based therapies |
Effective date | Existing CLAA framework | Amendment effective from 29 June 2026 |
Summary
India Expands Central Oversight of Advanced Therapies
The Ministry of Health and Family Welfare has expanded the Centrally License Approving Authority (CLAA) framework to include cell or stem cell-derived products, gene therapeutic products and xenografts, recognising that these advanced medical technologies require more specialised regulatory oversight than conventional pharmaceuticals. The amendment brings these products under the existing system of joint Central-State licensing with immediate effect.
Regulatory Framework Keeps Pace with Biomedical Innovation
India’s drug regulatory framework was originally designed around conventional medicines and established biological products. As regenerative medicine, gene therapies and other advanced biological treatments begin entering clinical practice, regulators increasingly need licensing systems capable of evaluating complex manufacturing processes, long-term safety considerations and specialised scientific evidence.
By extending the CLAA framework, rather than creating a new regulatory pathway, the Government builds on an existing institutional mechanism already used for selected high-risk biological products.
Greater Consistency in Licensing Standards
The amendment is intended to establish uniform national licensing standards for advanced therapies while retaining the joint role of Central and State Licensing Authorities. It also updates the Drugs Rules, 1945 and associated licensing forms to formally incorporate these new categories of products into India’s drug regulatory framework.
What is the Centrally License Approving Authority (CLAA)?
The Centrally License Approving Authority (CLAA) is a regulatory mechanism under the Drugs Rules, 1945 through which specified categories of critical drugs and biological products are licensed under the joint supervision of the Central and State Licensing Authorities. The framework is designed to ensure uniform regulatory standards for products requiring higher levels of scientific evaluation and regulatory oversight.
Policy Relevance
India’s drug regulatory framework is evolving alongside advances in biotechnology. Bringing advanced cell and gene therapies under the CLAA framework recognises that emerging medical technologies require more specialised scientific evaluation than conventional medicines.
A uniform national licensing framework can improve regulatory consistency for advanced therapies. Joint Central-State licensing helps establish common standards for products whose safety, manufacturing and clinical evaluation involve greater technical complexity.
Regulatory capacity will become increasingly important as advanced therapies expand. Effective implementation will depend on strengthening scientific expertise, inspection capability and technical assessment within drug regulatory institutions.
The amendment provides greater regulatory certainty for innovators and manufacturers. A clearly defined licensing pathway can support responsible development of regenerative medicine, gene therapy and other advanced biological products while maintaining patient safety.
The reform positions India’s regulatory framework to accommodate future therapeutic innovations. As personalised medicine, gene editing and cell-based therapies become more common, regulatory systems will need to adapt continuously without compromising quality, efficacy or safety standards.
Relevant Question for Policy Stakeholders: As advanced cell and gene therapies become more widely available in India, how can Central and State regulators build the specialised scientific expertise and regulatory capacity required to ensure timely licensing while maintaining rigorous safety and quality standards?
Follow the Full News Here: Centre Amends Drugs Rules, 1945 to Ensure Uniform Regulation of Advanced Cell and Gene Therapies